within Pharmacolibrary.Drugs.ATC.L;

model L01FF12
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.206 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 3 / 1000000,
    adminCount     = 1,
    Vd             = 0.004900000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Serplulimab is a fully human IgG4 monoclonal antibody inhibiting PD-1 (programmed cell death protein 1), used as an immune checkpoint inhibitor, primarily investigated and approved in China for the treatment of certain advanced or metastatic cancers, including microsatellite instability-high (MSI-H) solid tumors. As of 2024, it is not globally approved but is undergoing clinical studies in various indications.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic estimates in adult cancer patients based on phase I/II clinical study data; values reflect mean estimates post intravenous infusion.</p><h4>References</h4><ol><li><p>Ho, CL, et al., &amp; Lin, HY (2024). Safety, Tolerability, and Preliminary Efficacy of Serplulimab, a Novel Anti-PD-1 Antibody, in Patients with Metastatic or Recurrent Solid Tumors: A Phase I Study. <i>BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</i> 38(2) 287â€“299. DOI:<a href=&quot;https://doi.org/10.1007/s40259-023-00639-w&quot;>10.1007/s40259-023-00639-w</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38194016/&quot;>https://pubmed.ncbi.nlm.nih.gov/38194016</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01FF12;
